MCID: PTT003
MIFTS: 39

Pituitary-Dependent Cushing's Disease malady

Categories: Endocrine diseases

Aliases & Classifications for Pituitary-Dependent Cushing's Disease

Aliases & Descriptions for Pituitary-Dependent Cushing's Disease:

Name: Pituitary-Dependent Cushing's Disease 12 14 69
Pituitary-Dependent Cushing Disease 12
Pituitary Acth Hypersecretion 42
Overproduction of Acth 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3946
ICD10 33 E24.0
MeSH 42 D047748
NCIt 47 C113210
SNOMED-CT 64 190502001 9545009
UMLS 69 C0221406

Summaries for Pituitary-Dependent Cushing's Disease

MalaCards based summary : Pituitary-Dependent Cushing's Disease, also known as pituitary-dependent cushing disease, is related to pituitary adenoma, acth-secreting and burning mouth syndrome type 3. An important gene associated with Pituitary-Dependent Cushing's Disease is SST (Somatostatin), and among its related pathways/superpathways are Peptide ligand-binding receptors and Corticotropin-releasing hormone signaling pathway. The drugs Somatostatin and Liraglutide have been mentioned in the context of this disorder. Affiliated tissues include pituitary and testes, and related phenotypes are homeostasis/metabolism and endocrine/exocrine gland

Related Diseases for Pituitary-Dependent Cushing's Disease

Diseases related to Pituitary-Dependent Cushing's Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 75)
id Related Disease Score Top Affiliating Genes
1 pituitary adenoma, acth-secreting 11.5
2 burning mouth syndrome type 3 10.4 POMC SST
3 renal hypoplasia, bilateral 10.3 POMC SST
4 water-clear cell adenoma 10.3 POMC SST
5 vaginal adenoma 10.3 POMC SST
6 breast secretory carcinoma 10.3 CRH POMC SST
7 cerebral hemisphere lipoma 10.3 PRL SST
8 early-onset parkinson disease 10.3 CRH POMC SST
9 congenital tricuspid stenosis 10.3 POMC PRL TRH
10 rheumatic encephalitis 10.3 POMC PRL SST
11 gershoni-baruch syndrome 10.3 PRL TRH
12 nonparalytic poliomyelitis 10.2 CRH POMC PRL SST
13 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovasuclar malformations 10.2 CRH POMC PRL SST
14 kindler syndrome 10.2 GNRH1 POMC PRL
15 cleft lip palate-tetraphocomelia 10.2 CYP21A2 POMC
16 malignant otitis externa 10.2 CRH CYP21A2 POMC
17 hyperlipoproteinemia type iii 10.2 INS POMC
18 distal monosomy 14q 10.2 CYP21A2 POMC
19 african histoplasmosis 10.2 GNRH1 POMC PRL SST
20 extragonadal nonseminomatous germ cell tumor 10.2 GNRH1 POMC PRL SST
21 microphthalmia, syndromic 9 10.2 CYP21A2 NNT POMC
22 chondroma 10.2 INS POMC SST
23 astroblastoma 10.2 CRH GNRH1 POMC PRL
24 dacryoadenitis 10.2 CRH INS POMC PRL
25 loeffler endocarditis 10.1 CRH CYP21A2 POMC
26 hypermobility syndrome 10.1 CRH CYP21A2 POMC
27 fatty liver disease 10.1 CRH INS POMC PRL
28 endocrine organ benign neoplasm 10.1 CRH POMC PRL SST TRH
29 neurogenic arthropathy 10.1 GHRH INS POMC SST
30 body dysmorphic disorder 10.1 INS POMC PRL SST
31 aflatoxins-related hepatocellular carcinoma 10.1 INS POMC PRL TRH
32 epidural spinal canal meningioma 10.1 GNRH1 INS PRL
33 vertebral artery occlusion 10.1 GNRH1 INS POMC PRL
34 bile acid synthesis defect, congenital, 4 10.1 GNRH1 POMC PRL SST TRH
35 mucopolysaccharidosis type vi 10.1 GHR POMC PRL
36 spondylolysis 10.1 GNRH1 INS POMC PRL
37 acute gonococcal salpingitis 10.1 CRH GNRH1 POMC PRL TRH
38 hypoglycemic coma 10.1 CRH GNRH1 INS TRH
39 avoidant personality disorder 10.1 GNRH1 INS POMC PRL
40 intermittent squint 10.1 CRH GHRH GNRH1 POMC PRL
41 papillary craniopharyngioma 10.1 GNRH1 INS PRL TRH
42 vestibular gland benign neoplasm 10.1 INS POMC PRL SST TRH
43 benign peritoneal mesothelioma 10.1 CYP21A2 GNRH1 NNT POMC
44 ameloblastoma 10.1 CYP21A2 POMC PRKAR1A
45 cervix squamous papilloma 10.1 CRH GHRH INS POMC PRL
46 leukemia, acute promyelocytic, somatic 10.1 GHRH PRKAR1A PRL SST
47 pemphigus vegetans 10.0 GHR SST
48 immune system organ benign neoplasm 10.0 CRH GHRH POMC PRL SST TRH
49 bladder colonic type adenocarcinoma 10.0 POMC PRKAR1A PRL SST
50 esophagus squamous cell papilloma 10.0 CRH POMC PRKAR1A PRL SST

Graphical network of the top 20 diseases related to Pituitary-Dependent Cushing's Disease:



Diseases related to Pituitary-Dependent Cushing's Disease

Symptoms & Phenotypes for Pituitary-Dependent Cushing's Disease

MGI Mouse Phenotypes related to Pituitary-Dependent Cushing's Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.25 APEX1 CD59 CRH CYP27A1 GHR GHRH
2 endocrine/exocrine gland MP:0005379 10.22 GHRH GNRH1 HSD11B1 INS POMC PRKAR1A
3 growth/size/body region MP:0005378 10.18 POMC PRKAR1A SST TRH APEX1 CRH
4 behavior/neurological MP:0005386 10.17 MC3R POMC PRKAR1A PRL SERPINA6 SST
5 immune system MP:0005387 10.07 APEX1 CRH GHR GHRH GNRH1 HSD11B1
6 adipose tissue MP:0005375 10.06 CRH GHR HSD11B1 HTR4 INS MC3R
7 liver/biliary system MP:0005370 9.93 GNRH1 HSD11B1 INS POMC PRKAR1A PRL
8 nervous system MP:0003631 9.73 CRH CYP27A1 GHR GHRH GNRH1 HSD11B1
9 renal/urinary system MP:0005367 9.23 CD59 CRH CYP27A1 GHR GNRH1 INS

Drugs & Therapeutics for Pituitary-Dependent Cushing's Disease

Drugs for Pituitary-Dependent Cushing's Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Somatostatin Approved Phase 4,Phase 3,Phase 2 38916-34-6, 51110-01-1 53481605
2
Liraglutide Approved Phase 4 204656-20-2
3
Metformin Approved Phase 4 657-24-9 14219 4091
4
Zinc Approved Phase 4 7440-66-6 32051 23994
5 insulin Phase 4
6 Insulin, Globin Zinc Phase 4
7 Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
8 Hormones Phase 4,Phase 3,Phase 2,Early Phase 1
9 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
10 Dipeptidyl-Peptidase IV Inhibitors Phase 4
11 HIV Protease Inhibitors Phase 4
12 Hypoglycemic Agents Phase 4,Phase 2
13 Incretins Phase 4
14
protease inhibitors Phase 4
15 Sitagliptin Phosphate Phase 4
16
Lactitol Phase 4 585-86-4 3871
17
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2 50-23-7 5754 657311
18
Cabergoline Approved Phase 3,Phase 2 81409-90-7 54746
19
Dopamine Approved Phase 3,Phase 2 51-61-6, 62-31-7 681
20
Mifepristone Approved, Investigational Phase 3,Phase 2 84371-65-3 55245
21
Epinephrine Approved, Vet_approved Phase 3,Phase 2 51-43-4 5816
22
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
23 Cortisol succinate Phase 3,Phase 2
24 Hydrocortisone 17-butyrate 21-propionate Phase 3,Phase 2
25 Hydrocortisone acetate Phase 3,Phase 2
26 Adrenocorticotropic Hormone Phase 3,Phase 2,Early Phase 1
27 beta-endorphin Phase 3,Phase 2
28 Melanocyte-Stimulating Hormones Phase 3,Phase 2
29 Antiparkinson Agents Phase 3,Phase 2
30 Dopamine Agents Phase 3,Phase 2
31 Dopamine agonists Phase 3,Phase 2
32 Neurotransmitter Agents Phase 3,Phase 2
33 Contraceptive Agents Phase 3,Phase 2
34 Contraceptives, Oral Phase 3,Phase 2
35 Contraceptives, Postcoital Phase 3,Phase 2
36 Luteolytic Agents Phase 3,Phase 2
37 Epinephryl borate Phase 3,Phase 2
38 Racepinephrine Phase 3,Phase 2
39 Antineoplastic Agents, Hormonal Phase 3,Phase 2
40 Edotreotide Phase 3
41 Gastrointestinal Agents Phase 3,Phase 2
42 Radiopharmaceuticals Phase 3
43 Orange Nutraceutical Phase 3
44
Bexarotene Approved, Investigational Phase 1, Phase 2 153559-49-0 82146
45
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
46
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
47
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
48
Rosiglitazone Approved, Investigational Phase 2 122320-73-4 77999
49
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
50
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938

Interventional clinical trials:

(show all 50)
id Name Status NCT ID Phase
1 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4
2 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Recruiting NCT02060383 Phase 4
3 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4
4 Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease Completed NCT01374906 Phase 3
5 Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed NCT00434148 Phase 3
6 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Completed NCT01582061 Phase 3
7 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3
8 Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3
9 An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00936741 Phase 3
10 A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00569582 Phase 3
11 Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease Recruiting NCT02180217 Phase 3
12 Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease Recruiting NCT02697734 Phase 3
13 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Recruiting NCT02419664 Phase 3
14 Mifepristone in Children With Refractory Cushing's Disease Withdrawn NCT01925092 Phase 3
15 Preoperative Bexarotene Treatment for Cushing's Disease Unknown status NCT00845351 Phase 1, Phase 2
16 Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease Unknown status NCT02484755 Phase 2
17 Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease Completed NCT00171951 Phase 2
18 A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease Completed NCT00088608 Phase 2
19 Treatment of Cushing's Disease With R-roscovitine Recruiting NCT02160730 Phase 2
20 Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome Recruiting NCT02468193 Phase 2
21 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Recruiting NCT00939523 Phase 2
22 Study to Evaluate CORT125134 in Patients With Cushing's Syndrome Recruiting NCT02804750 Phase 2
23 Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease Active, not recruiting NCT01915303 Phase 2
24 Safety and Efficacy of LCI699 in Cushing's Disease Patients. Active, not recruiting NCT01331239 Phase 2
25 Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition Not yet recruiting NCT03111810 Phase 2
26 Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment Not yet recruiting NCT02713776 Phase 2
27 Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease) Terminated NCT00612066 Phase 2
28 Rosiglitazone in Treating Patients With Pituitary Tumors Terminated NCT00616642 Phase 2
29 Pasireotide Therapy in Patients With Nelson's Syndrome Terminated NCT01617733 Phase 2
30 Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion Terminated NCT00422201 Phase 2
31 Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma Terminated NCT00813592 Phase 2
32 Study of Depression, Peptides, and Steroids in Cushing's Syndrome Unknown status NCT00004334
33 Anesthesia Management of Retroperitoneal Adrenalectomies Unknown status NCT00894335
34 The Factors Associated With the Recurrence in Patients With Cushing Disease Completed NCT02233335
35 Cognition, Steroids, and Imaging in Cushings Disease Completed NCT00081341
36 Jugular Vein Sampling for Hormone Levels for the Diagnosis of Cushing Syndrome Completed NCT00001453
37 Examination of Brain Serotonin Receptors in Patients With Mood Disorders Completed NCT00026832
38 Obesity as a Risk Factor for Musculoskeletal Diseases in the U.S. Air Force: Associations and Implications for Force Readiness Completed NCT01613001
39 Cushing's Disease Complications Recruiting NCT02568982
40 Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease Recruiting NCT02310269
41 Effects of Hormone Stimulation on Brain Scans for Cushing s Disease Recruiting NCT01459237 Early Phase 1
42 Adrenal Venous Sampling in Patients With Overt or Subclinical Cushings Syndrome, and Bilateral Adrenal Tumors Recruiting NCT02543697
43 Mutations of Glucocorticoid Receptor in Bilateral Adrenal Hyperplasia Recruiting NCT02810496
44 An Investigation of Pituitary Tumors and Related Hypothalmic Disorders Recruiting NCT00001595
45 Mifepristone for Breast Cancer Patients With Higher Levels of Progesterone Receptor Isoform A Than Isoform B. Recruiting NCT02651844
46 Cushing´s Disease Epidemiology in Sweden Active, not recruiting NCT02350153
47 Rhinological Outcomes in Endonasal Pituitary Surgery Active, not recruiting NCT01504399
48 Assessment of Persistent Cognitive Impairment After Cure of Cushing's Disease Not yet recruiting NCT02603653
49 Long-term Cardiovascular Risk in Cured Cushing's Patients Terminated NCT00881283
50 A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia Terminated NCT00796783

Search NIH Clinical Center for Pituitary-Dependent Cushing's Disease

Cochrane evidence based reviews: pituitary acth hypersecretion

Genetic Tests for Pituitary-Dependent Cushing's Disease

Anatomical Context for Pituitary-Dependent Cushing's Disease

MalaCards organs/tissues related to Pituitary-Dependent Cushing's Disease:

39
Pituitary, Testes

Publications for Pituitary-Dependent Cushing's Disease

Articles related to Pituitary-Dependent Cushing's Disease:

(show all 13)
id Title Authors Year
1
Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. ( 18957506 )
2009
2
Greater disorderliness of ACTH and cortisol release accompanies pituitary-dependent Cushing's disease. ( 9150699 )
1997
3
Risk factors and long-term outcome in pituitary-dependent Cushing's disease. ( 8675592 )
1996
4
Failure of hypophysectomy to correct pituitary-dependent Cushing's disease in two patients. ( 3190383 )
1988
5
Corticotrophin-releasing factor-test used with bilateral, simultaneous inferior petrosal sinus blood-sampling for the diagnosis of pituitary-dependent Cushing's disease. ( 2820618 )
1986
6
Is it possible to diagnose pituitary-dependent Cushing's disease? ( 3000267 )
1985
7
A case of pituitary dependent Cushing's disease with clinical and biochemical features of the ectopic ACTH syndrome. ( 2985302 )
1985
8
Sodium valproate and metyrapone for pituitary-dependent Cushing's disease. ( 6147673 )
1984
9
Simultaneous bilateral venous sampling for adrenocorticotropin in pituitary-dependent cushing's disease: evidence for lateralization of pituitary venous drainage. ( 6311861 )
1983
10
Responsiveness of the hypophyseal-adrenocortical axis to corticotropin-releasing factor in pituitary-dependent Cushing's disease. ( 6308029 )
1983
11
Remission of pituitary-dependent Cushing's disease after removal of nonneoplastyic pituitary gland. ( 6252859 )
1980
12
Pituitary-dependent Cushing's disease. ( 858043 )
1977
13
Pituitary-dependent Cushing's disease. ( 193608 )
1977

Variations for Pituitary-Dependent Cushing's Disease

Expression for Pituitary-Dependent Cushing's Disease

Search GEO for disease gene expression data for Pituitary-Dependent Cushing's Disease.

Pathways for Pituitary-Dependent Cushing's Disease

GO Terms for Pituitary-Dependent Cushing's Disease

Cellular components related to Pituitary-Dependent Cushing's Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 CD59 CRH GHR GHRH GNRH1 INS
2 extracellular region GO:0005576 9.36 CD59 CRH GHR GHRH GNRH1 INS
3 secretory granule GO:0030141 9.33 POMC PRL TRH
4 endosome lumen GO:0031904 9.26 INS PRL

Biological processes related to Pituitary-Dependent Cushing's Disease according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 female pregnancy GO:0007565 9.65 CRH GNRH1 PRL
2 response to corticosterone GO:0051412 9.51 CRH TRH
3 positive regulation of cAMP biosynthetic process GO:0030819 9.5 CRH GHRH MC3R
4 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.49 GHR PRL
5 parturition GO:0007567 9.46 CRH PRL
6 response to ethanol GO:0045471 9.46 CRH GNRH1 PRL TRH
7 ovulation cycle GO:0042698 9.43 GNRH1 PRL
8 cell-cell signaling GO:0007267 9.43 GHRH GNRH1 INS POMC SST TRH
9 regulation of appetite GO:0032098 9.4 HTR4 POMC
10 negative regulation of feeding behavior GO:2000252 9.37 INS TRH
11 hormone-mediated apoptotic signaling pathway GO:0008628 9.26 CRH SST
12 glucocorticoid biosynthetic process GO:0006704 8.8 CRH CYP21A2 HSD11B1

Molecular functions related to Pituitary-Dependent Cushing's Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.17 CRH GNRH1 INS POMC PRL SST
2 steroid hydroxylase activity GO:0008395 8.96 CYP21A2 CYP27A1

Sources for Pituitary-Dependent Cushing's Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....